# NCT02013219 (NCT02013219)

> A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)

No report yet. It can be ordered.

- Drugs tested: atezolizumab plus erlotinib; atezolizumab plus alectinib
- Indication: advanced non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02013219
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Alectinib; Atezolizumab; Erlotinib
- Enrollment: 52
- Primary outcome: Percentage of Participants with Dose-Limiting Toxicities (DLTs)
- Primary outcome: Recommended Phase II Dose (RP2D) of Atezolizumab and Erlotinib
- Primary outcome: Recommended RP2D of Atezolizumab and Alectinib

## Indexed commentary on NCT02013219 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct02013219